RS viral infection
Conditions
Interventions
Vitamin D3 (Cholecalciferol)
lt 3.0kg: (exclusion criteria)
[3.0-6.0) kg: 500IU
[6.0-8.5) kg: 750 IU
[8.5-11.5) kg: 1000 IU
[11.5 kg: 1250 IU
or Placebo
D002762
Sponsors
Takahashi Kyohei
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Rapid antigen testing or PCR for the respiratory syncytial virus is positive (2) Patients between 2 months and 36 months old. (3) Parents or guardians have given consent to participate in this study
Exclusion criteria
Exclusion criteria: (1) If the patient weighs less than 3 kg at the time of admission (2) When palivizumab (Synagis) is being administered or is indicated for administration (3) Comorbidities such as chromosomal abnormalities or respiratory diseases which may affect the course of RS virus infection. (4) Cases requiring ventilatory management at the time of admission (5) Use of a vitamin D product (either prescription or supplement) from birth to the time of registration (6) If the principal investigator or research co-investigator determines that participation is inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalance of wheezing for 12 months after entry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of administration Intubation management, intensive care, and death after admission Days of oxygen use during hospitalization Number of days until oral intake can be started Serum 25-(OH)D and Ca concentration before and 2 weeks after treatment Number/Timing of wheezing for 12 months after entry Adverse event | — |
Contacts
Public ContactKyohei Takahashi
National Hospital Organization Sagamihara National Hospital
Outcome results
None listed